Compare Amgen, Inc. (AMGN) vs iShares MSCI South Korea ETF (EWY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs iShares MSCI South Korea ETF — how do they compare? Amgen, Inc. trades at $362.14 (market cap $196.12B), while iShares MSCI South Korea ETF trades at $169.45. The key difference: Amgen, Inc. pays a 2.77% dividend while iShares MSCI South Korea ETF pays none, and Amgen, Inc. is trading nearer its 52-week high, iShares MSCI South Korea ETF nearer its low. Which is the better fit depends on your goals.
| AMGN | EWY | |
|---|---|---|
Market Cap | $196.12B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $388.16 | $219.20 |
52-Week Low | $271.18 | $70.65 |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
EWY, the iShares MSCI South Korea ETF, is trading at $183.52, down 0.62% amid bearish technical signals. The ETF faces headwinds from South Korea's Kospi Index entering a local bear market, declining 21% from its YTD high. Heavy concentration in Samsung and SK Hynix exposes EWY to AI chip volatility, with recent earnings pressure from weak EV demand at LG Energy Solution. Technical indicators show a bearish moving average crossover and ADX signaling strong downtrend momentum.
Despite the pullback, EWY remains a leveraged play on AI semiconductor demand through its top holdings. The outlook hinges on sustained AI memory demand and Samsung's performance, with potential upside from SK Hynix's planned U.S. listing. Key risks include single-stock concentration, global tech volatility, and Korea's delayed developed-market status. The current bearish trend suggests cautious entry points near support at $179-180 may offer better risk-reward.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About iShares MSCI South Korea ETF
EWY tracks the MSCI Korea 25/50 Index, offering targeted exposure to large and mid-cap companies in South Korea. It is structurally centered on the global technology supply chain, industrials, and financial services, serving as a liquid tool for investors seeking a single-country view of this advanced, innovation-led economy.
Read more on EWY →
